TOKYO and BASKING RIDGE, N.J., June 21, 2019 — (Healthcare Sales &Marketing Network) — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Ad… Biopharmaceuticals, Oncology, FDA Daiichi Sankyo, quizartinib, acute myeloid leukemia, FLT3 inhibitor
Publication date: Available online 1 August 2019Source: Stem Cell ReportsAuthor(s): Juan Bautista Menendez-Gonzalez, Milica Vukovic, Ali Abdelfattah, Lubaid Saleh, Alhomidi Almotiri, Leigh-anne Thomas, Aloña Agirre-Lizaso, Aleksandra Azevedo, Ana Catarina Menezes, Giusy Tornillo, Sarah Edkins, Kay Kong, Peter Giles, Fernando Anjos-Afonso, Alex Tonks, Ashleigh S. Boyd, Kamil R. Kranc, Neil P. RodriguesSummarySubversion of transcription factor (TF) activity in hematopoietic stem/progenitor cells (HSPCs) leads to the development of therapy-resistant leukemic stem cells (LSCs) that drive fulminant acute myeloid leukemia…
Publication date: Available online 1 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Evandro D. Bezerra, Megan Othus, Carole Shawn, Mary-Elizabeth Percival, Kelda Gardner, Roland B. Walter, Pamela S. Becker, Paul C. Hendrie, Elihu H. Estey
Growing evidence has demonstrated that epigenetic dysregulation is a common pathological feature in human cancer cells. Global alterations in the epigenetic landscape are prevalent in malignant cells across different solid tumours including, prostate cancer, non-small-cell lung cancer, renal cell carcinoma, and in haemopoietic malignancy. In particular, DNA hypomethylation and histone hypoacetylation have been observed in acute myeloid leukaemia (AML) patient blasts, with histone methylation being an emerging area of study.
Histone 3 lysine 9 trimethylation (H3K9me3) is a post-translational modification known to be invol…
Acute myeloid leukemia (AML) is characterized by the accumulation of immature white blood cell precursors in the bone marrow and peripheral circulation. In essence, leukemic cells fail to differentiate and are stalled at a particular step of hematopoietic maturation and are unable to complete their development into functional blood cells with a finite life cycle. They are thus said to possess a “differentiation block.” Pharmacological override of this block is one attractive avenue of therapy, termed “differentiation therapy.” The most successful example of this therapeutic strategy is…
Authors: Liu Z, Hua Y, Liu C, Cheng S
PMID: 31359748 [PubMed – as supplied by publisher]
PMID: 31371420 [PubMed – as supplied by publisher]
In an effort to identify target genes in acute myeloid leukemia, we compared gene expression profiles between normal and acute myeloid leukemia cells from various publicly available datasets. We identified CD99, a gene that is upregulated in patients with acute myeloid leukemia. In 186 patients from The Cancer Genome Atlas – acute myeloid leukemia dataset, CD99 was overexpressed in patients with FLT3-ITD and was downregulated in patients with TP53 mutations. CD99 is a transmembrane protein expressed on leukocytes and plays a role in cell adhesion, trans-endothelial migration and T cells differentiation. C…
In conclusion, TARP qualifies as a relevant target for immunotherapeutic T-cell therapy in acute myeloid leukemia.
PMID: 31371409 [PubMed – as supplied by publisher]
Minimal residual disease has emerged as an important prognostic factor for relapse and survival in acute myeloid leukemia. Eradication of minimal residual disease may increase the number of patients with long-term survival; however, to date, strategies that specifically target minimal residual disease are limited. Consensus guidelines on minimal residual disease detection by immunophenotypic and molecular methods are an essential initial step for clinical trials evaluating minimal residual disease. Here, we review promising targets of minimal residual disease prior to allogeneic stem cell transplantation….